List of Doptelet drug patents

Doptelet is owned by Akarx Inc.

Doptelet contains Avatrombopag Maleate.

Doptelet has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Doptelet are:

  • US8765764

Doptelet was authorised for market use on 21 May, 2018.

Doptelet is available in tablet;oral dosage forms.

Doptelet can be used as treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure, treatment of thrombocytopenia in an adult patient with chronic immune thrombocytopenia who has had an insufficient response to a previous treatment.

Drug patent challenges can be filed against Doptelet from 2022-05-21.

The generics of Doptelet are possible to be released after 26 June, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7638536 AKARX INC 2-Acylaminothiazole derivative or salt thereof
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765764 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jan, 2023

(2 months ago)

US8338429 AKARX INC 2-acylaminothiazole derivative or salt thereof
Jun, 2023

(2 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 21, 2023
Orphan Drug Exclusivity (ODE) Jun 26, 2026

Drugs and Companies using AVATROMBOPAG MALEATE ingredient

NCE-1 date: 2022-05-21

Market Authorisation Date: 21 May, 2018

Treatment: Treatment of thrombocytopenia in an adult patient with chronic liver disease who is scheduled to undergo a procedure using doptelet; Treatment of thrombocytopenia in an adult patient with chronic live...

Dosage: TABLET;ORAL

More Information on Dosage

DOPTELET family patents

5

Japan

4

United States

2

Spain

2

European Union

1

Luxembourg

1

Belgium

1

Hungary

1

Slovenia

1

Portugal

1

Denmark

1

Cyprus

1

Canada

1

Netherlands

1

Korea, Republic of

1

China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in